CN105198972B - 一种高纯度重组人脑利钠肽的制备方法 - Google Patents
一种高纯度重组人脑利钠肽的制备方法 Download PDFInfo
- Publication number
- CN105198972B CN105198972B CN201510625028.9A CN201510625028A CN105198972B CN 105198972 B CN105198972 B CN 105198972B CN 201510625028 A CN201510625028 A CN 201510625028A CN 105198972 B CN105198972 B CN 105198972B
- Authority
- CN
- China
- Prior art keywords
- natriuretic peptide
- brain natriuretic
- human brain
- recombinant human
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 241000894006 Bacteria Species 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 230000004927 fusion Effects 0.000 claims abstract description 30
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 28
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 28
- 239000013604 expression vector Substances 0.000 claims abstract description 15
- 241000588724 Escherichia coli Species 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 150000001413 amino acids Chemical group 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract description 12
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract description 11
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract description 11
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract description 11
- 230000004071 biological effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510625028.9A CN105198972B (zh) | 2015-09-28 | 2015-09-28 | 一种高纯度重组人脑利钠肽的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510625028.9A CN105198972B (zh) | 2015-09-28 | 2015-09-28 | 一种高纯度重组人脑利钠肽的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105198972A CN105198972A (zh) | 2015-12-30 |
CN105198972B true CN105198972B (zh) | 2020-04-21 |
Family
ID=54946958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510625028.9A Active CN105198972B (zh) | 2015-09-28 | 2015-09-28 | 一种高纯度重组人脑利钠肽的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105198972B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106544346A (zh) * | 2016-11-03 | 2017-03-29 | 山东维真生物科技有限公司 | 促进bnp蛋白过表达的重组载体及其构建方法和腺相关病毒 |
CN108220315A (zh) * | 2016-12-22 | 2018-06-29 | 珠海冀百康生物科技有限公司 | 一种小分子蛋白或多肽的制备方法及融合蛋白 |
CN107177649B (zh) * | 2017-06-22 | 2020-03-20 | 西藏诺迪康药业股份有限公司 | 一种提高重组人脑利钠肽融合蛋白表达量的发酵工艺 |
CN109535244B (zh) * | 2018-12-11 | 2020-12-01 | 上海景峰制药有限公司 | 一种重组人脑利钠肽的纯化方法 |
CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594581A (zh) * | 2004-07-16 | 2005-03-16 | 深圳大学 | 一种基因工程重组技术制备人脑利钠肽的方法 |
CN102392041A (zh) * | 2011-12-08 | 2012-03-28 | 重庆科润生物医药研发有限公司 | 一种重组人促肾上腺皮质激素释放因子的制备方法 |
CN103923937A (zh) * | 2014-04-09 | 2014-07-16 | 石家庄沃泰生物科技有限公司 | 一种可溶性表达人脑利钠肽重组蛋白的方法和应用 |
-
2015
- 2015-09-28 CN CN201510625028.9A patent/CN105198972B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594581A (zh) * | 2004-07-16 | 2005-03-16 | 深圳大学 | 一种基因工程重组技术制备人脑利钠肽的方法 |
CN102392041A (zh) * | 2011-12-08 | 2012-03-28 | 重庆科润生物医药研发有限公司 | 一种重组人促肾上腺皮质激素释放因子的制备方法 |
CN103923937A (zh) * | 2014-04-09 | 2014-07-16 | 石家庄沃泰生物科技有限公司 | 一种可溶性表达人脑利钠肽重组蛋白的方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105198972A (zh) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105198972B (zh) | 一种高纯度重组人脑利钠肽的制备方法 | |
WO2020182229A1 (zh) | 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法 | |
CN113502296B (zh) | 一种表达司美鲁肽前体的重组工程菌及其构建方法 | |
ES2375330T3 (es) | Expresión directa de péptidos en medios de cultivo. | |
WO2019153827A1 (zh) | 一种利拉鲁肽中间体多肽的制备方法 | |
CN101519446A (zh) | 一种重组人胰岛素及其类似物的制备方法 | |
CN106434717A (zh) | 一种生物合成制备人glp‑1多肽或其类似物的方法 | |
CN107245494A (zh) | Aβ42在大肠杆菌中的高效可溶性表达及纯化方法 | |
WO2022012020A1 (zh) | Glp-1类似物多肽的制备方法及在ⅱ型糖尿病中应用 | |
CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
CN107881187A (zh) | 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用 | |
JP2005515167A (ja) | インスリン分泌性glp−1(7−36)ポリペプチドおよび/またはglp−1類似体を生成する方法 | |
CN112584853A (zh) | 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法 | |
WO2023125178A1 (zh) | 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法 | |
WO2019082138A1 (en) | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE | |
CN101525387B (zh) | 重组长效胰高血糖素样肽类似物及其制备方法 | |
CN106390100B (zh) | 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
RU2006137635A (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pHINS11, КОДИРУЮЩАЯ ГИБРИДНЫЙ БЕЛОК - ПРЕДШЕСТВЕННИК ИНСУЛИНА ЧЕЛОВЕКА, КЛЕТКА ESCHERICHIA COLI, ТРАНСФОРМИРОВАННАЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pHINS11, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pHINS11 - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА - ПРЕДШЕСТВЕННИКА ИНСУЛИНА ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ИНСУЛИНА ЧЕЛОВЕКА | |
CN114933658B (zh) | 一种短肽元件及其应用方法 | |
CN113249288B9 (zh) | 一种表达glp-1类似物的重组菌及其应用 | |
CN105884901B (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
CN107188953B (zh) | 胰高血糖素样肽-1类似物及其用途 | |
WO2021136521A1 (zh) | 多肽及其应用 | |
CN109776653B (zh) | 一种人血清白蛋白黏附肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200924 Address after: 274000 No. 99, Kunming Road, peony Industrial Park, Shandong, Heze Patentee after: Shandong Danhong Pharmaceutical Co.,Ltd. Address before: 401121 north of the city of Chongqing New District Science and Technology Park Development Center North Wing mercury factory building 5 Building No. 1 Patentee before: CHONGQING KERUN BIOMEDICAL R & D Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210316 Address after: No. 1236, West Kangle Avenue, pharmaceutical industrial park, Luzhou hi tech Zone, Luzhou City, Sichuan Province Patentee after: Sichuan Luzhou Buchang biopharmaceutical Co.,Ltd. Address before: 274000 No. 99 Kunming Road, Heze Mudan Industrial Park, Shandong Province Patentee before: Shandong Danhong Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240102 Address after: No. 128, Xinghua East Road, Dingxing County, Baoding City, Hebei Province 072650 Patentee after: BAODING TIANHAO PHARMACEUTICAL Co.,Ltd. Address before: No. 1236, West Kangle Avenue, pharmaceutical industrial park, Luzhou hi tech Zone, Luzhou City, Sichuan Province Patentee before: Sichuan Luzhou Buchang biopharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |